Navigation Links
Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
Date:8/20/2008

Collaboration Will Seek to Identify microRNAs Implicated in HIV Viral

Replication and Their Function Samples Will be Screened and Analyzed Using Rosetta Genomics' Proprietary

microRNA Technologies

REHOVOT, Israel and JERSEY CITY, New Jersey, August 20 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today a collaboration with the National Institute of Health to identify microRNAs involved in the progression of the Human Immunodeficiency Virus (HIV), that may be used as potential drug targets.

Rosetta Genomics has access to the majority of known human and viral microRNAs. From this strong intellectual property position, the company has developed highly sensitive, proprietary technologies to detect and quantify microRNAs. These technologies are based on publicly known human and viral microRNAs in addition to Rosetta Genomics proprietary microRNAs, which are yet to be published. Leveraging Rosetta Genomics' extensive know-how in microRNAs and proprietary technologies, this collaboration will seek to determine the role of microRNAs in HIV viral replication, and their potential to act as novel drug targets for future therapy.

"We are very excited to be collaborating with the NIH in seeking to better understand the link between the aberrant expression of microRNAs and the viral replication of HIV, and to identify potential microRNA drug targets", said Dr. Zvi Bentwich, Chief Scientist of Rosetta Genomics and a world renowned HIV researcher. "Having the opportunity to work with the NIH on this important collaboration is a reflection on our leading capabilities and know how in this field."

In a study published last year (Zhang et al. Nature Medicine, 2007), researchers showed that microRNAs are involved in suppressing HIV replication' and keeping it latent. Through this collaboration, Rosetta Genomics and the NIH aim to deepen the understanding of the role microR
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Reports Second Quarter 2008 Financial Results
2. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
3. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
4. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
5. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
6. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
7. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
8. /C O R R E C T I O N -- Rosetta Genomics Ltd/
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
11. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2
... Vaccine Induced Neutralizing Antibodies and Protected Mice upon ChallengeROCKVILLE, ... NVAX ) announced results from a preclinical study of ... the viral fusion (F) protein. The virus utilizes ... respiratory tract and cause illness. Novavax,s RSV-F ...
... Boston Scientific Corporation (NYSE: BSX ) ... ended December 31, 2008. Subsequent to the release ... a patent litigation settlement and, as expected, finalized a ... U.S. Generally Accepted Accounting Principles, these events are required ...
... 26 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... December 31, 2008. InterMune reported a net loss for ... share, compared with a,net loss of $25.9 million, or $0.67 ... Dan Welch, Chairman, Chief Executive Officer and ...
Cached Biology Technology:NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 2NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 3NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 4Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 2Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 3Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 4Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 5Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 6Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 7Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 8Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 9Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 10InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 2InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 3InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 4InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 5InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 6InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 7InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 8InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 9InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 10InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 11InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 12
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2
... awarded a three-year grant from the U.S. Department ... economic impacts of the "biofuels revolution" on rural ... comes from the department,s Ethical, Legal and Societal ... Genomes or Nanotechnologies program. The researchers from K-State,s ...
... have a soft spot for Botswana, developed while reading ... have had a chance to do any sleuthing of ... when University of Illinois scientist Karen Chapman-Novakofski acquired a ... about the health and nutrition of that country,s elderly. ...
... at the University of Leeds have made a breakthrough ... greatest global disease threats to wild carnivores including lions, ... The discovery of how canine distemper Virus (CDV) jumps ... to a more effective monitoring and control of the ...
Cached Biology News:K-State sociologists use Department of Energy grant 2U of I scientist does nutritional detective work in Botswana 2U of I scientist does nutritional detective work in Botswana 3Research sheds new light on how diseases jump across species 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Biology Products: